Asia, home to over half the world's population, is experiencing a rise in non-communicable diseases and accelerated aging. This, coupled with insufficient government investment in public healthcare, is creating a significant funding gap. According to Abrar Mir, co-founder of Quadria Capital, Asia leads globally in patients with diabetes, cancer, and cardiovascular diseases. The healthcare market in Asia could reach $5 trillion by 2030, contributing 40% of the global sector's growth.

However, healthcare spending in Asia accounts for only 20% of global spending, highlighting the need for increased financing. The situation is particularly critical in Southeast Asia, where non-communicable diseases claim millions of lives annually, driven by factors such as smoking, alcohol consumption, and physical inactivity.

Countries like Thailand are rapidly becoming 'ultra-aged' societies, with more people over 60 than under 15. ASEAN governments allocate less than 4% of their GDP to healthcare, compared to 9% in OECD countries. This disparity opens space for private capital, which already plays a crucial role in the region's social infrastructure. Mir notes that private capital is essential for building social infrastructure, and without it, many people would lack access to basic healthcare.

Quadria Capital, with approximately $4.2 billion in assets under management, invests in healthcare companies across Southeast Asia, including Hermina Hospitals in Indonesia, Straits Orthopaedics in Malaysia, and Con Cung in Vietnam. The firm collaborates with sovereign wealth funds, development finance institutions, and impact investors.

Asia is rapidly advancing in the biopharma value chain. In 2024, the region accounted for over 85% of the growth in innovative drug pipelines, led by China and South Korea. That same year, the region generated almost two-thirds of the world’s biotech patent grants, exceeding Europe's output by five times.

Southeast Asia, however, is at a different stage of development, attracting global firms for its low production costs rather than its healthcare innovation. Mir believes that, over time, this situation will evolve towards innovation, as has already happened in China.

Despite the challenges, Mir concludes that the healthcare sector in Asia holds immense potential. Healthcare companies must have a clear strategy for Asia to remain global leaders. Mir states: “We can do it better and cheaper.”

The combination of an aging population, the rise of chronic diseases, and the region's growing wealth, along with insufficient public investment, creates a unique opportunity for private capital in the Asian healthcare sector.